Episurf Medical’s 50th Episealer® implant in Germany demonstrates rapid clinical adoption
Episurf Medical announces that the 50th implantation in Germany of the Episealer® knee implant will take place in the coming days. Episurf Medical intensified its activities in Germany during 2016 and the company’s technology has been very well received by key surgeons in the country. Germany is one of the company's prioritized markets.
“In Germany we started our efforts in the regions around Berlin, Hamburg and Münster with great results. We then continued to focus on additional German regions and have today a sales team covering all parts of Germany. The clinical feedback from surgeons and patients in Germany is very positive and our surgeons have accepted the Episealer® as one of their standard treatments, so we look forward to helping more patients back to an active life without knee pain“, says Dirk Tretau, Regional Manager for Episurf Medical in North and West Germany.
“We are very happy that our early users in Germany contributed to a rate of more than one implantation every second week during 2016 in Germany. We are in the early days of our commercialisation, and we couldn’t have asked for a better start in Germany. It’s all about starting on a limited scale and producing good clinical results, just as we are doing. Dirk and his colleagues are doing a great job which continues in 2017”, says Pål Ryfors, acting CEO and CFO of Episurf Medical.
For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.30 CET on 3 April 2017.